Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2086 in Adults with Narcolepsy
jRCT2031260074Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of E2086 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) (4 cohorts), sponsored by Eisai Co., Ltd. Primary endpoint: Change from Baseline to Week 4 in Mean Sleep Latency on MWT. Started Apr 2026; status: recruiting.
02
Drugs
E2086
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on jRCT2031260074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260074.